The 2020 American College of Cardiology Scientific Sessions occurred in the context of an incredibly challenging period where all were and continue to be impacted by the COVID pandemic. The implications of COVID were broad in that many participants and attendees are on the frontline helping patients; all of us are impacted personally no matter where we live; travel was impossible; and scientific priorities were largely focused on COVID. These implications rapidly unfolded in the weeks preceding the planned Scientific Sessions in Chicago and required the rapid and dynamic pivot to a virtual meeting that would enable the scientific community to come together and disseminate high-quality science in an effective format. In spite of these challenges, landmark trials including VOYAGER PAD, VICTORIA, and CARAVAGGIO as well as many other studies were presented online with panel discussion, QA, and dynamic chat.
In the following pages you will find a comprehensive review of this landmark virtual meeting and summaries of pivotal trials and impactful studies. We hope you find this report to be useful and informative. Thank you for your interest and most of all we wish you all the best, hope you and your families are safe and healthy, and express our thanks to all who are doing what they can to help in this critical and challenging time.
Marc Bonaca
Posted on
Previous Article
« Rivaroxaban and aspirin effective and safe for PAD patients Next Article
Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer »
« Rivaroxaban and aspirin effective and safe for PAD patients Next Article
Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer »
Table of Contents: ACC/WCC 2020
Featured articles
Heart Failure and Cardiomyopathies
Mavacamten shows promising results in non-obstructive hypertrophic cardiomyopathy
Vericiguat shows beneficial effects in a very high-risk HF population
No role for sodium nitrite in out-of-hospital cardiac arrest
Vascular Medicine and Thromboembolism
Rivaroxaban and aspirin effective and safe for PAD patients
TAILOR-PCI misses endpoint but still provides valuable insights
Edoxaban: alternative to warfarin after surgical aortic or mitral valve procedures?
Bleeding reduction post-TAVI with OAC alone vs OAC + clopidogrel
Apixaban offers new perspective for cancer patients in need of anticoagulation
Rivaroxaban superior to enoxaparin in preventing VTE in non-major orthopaedic surgery
Interventional Cardiology
TAVR safe and effective in low-risk bicuspid aortic stenosis patients
TAVR model reveals differences in hospital outcomes
2-year results show non-significant outcomes TAVR vs surgery in severe aortic stenosis
Renal denervation better than sham for blood pressure
Infusion of ethanol in the vein of Marshall for persistent AF
Atrial Fibrillation/Acute Coronary Syndrome
Fewer adverse events with ticagrelor monotherapy after 3 months DAPT
TWILIGHT sub-study: same outcomes for diabetes patients
TWILIGHT sub-study: complex PCI patients
LAAO Watchman registry data positive
Apixaban in AF patients with recent ACS/PCI: Drop aspirin after 30 days
Genetics and Prevention
Homozygous FH responds to alirocumab
Evinacumab significantly reduces LDL-C in homozygous FH patients
Higher serum levels of eicosapentaenoic acid correlate with reduced CV events
Quit smoking: vaping + counselling helps
Related Articles
September 8, 2020
LAAO Watchman registry data positive
September 7, 2020
Letter from the Editor
September 7, 2020
Subgroup analysis VOYAGER PAD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com